Cardiff Oncology Inc (CRDF) FinancialsCRDFCardiff Oncology Inc

Evaluating the bottom line, Cardiff Oncology, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -9245.19%, while the net margin is -8876.92%. These profitability ratios, combined with a Return on Equity (ROE) of -94.14%, provide a clear picture of how effectively CRDF converts its operational activities into shareholder value.

In the context of the broader market, CRDF competes directly with industry leaders such as OM and NRXS. With a market capitalization of $77.64M, it holds a significant position in the sector. When comparing efficiency, CRDF's gross margin of 100.00% stands against OM's 41.99% and NRXS's 85.87%. Such benchmarking helps identify whether Cardiff Oncology, Inc. is trading at a premium or discount relative to its financial performance.

The company reported a net loss of $9.24 million in Q2, down from $13.95 million the previous year, indicating some improvement in financial performance. However, the company has a forward P/E ratio of 0, indicating a lack of earnings expectations, and a gross margin of 100%, which is positive but does not offset the losses.